Abnormal cell growth can lead to cancer. Cells that grow uncontrollably invade nearby tissues and further spread to other parts of the body through the lymphatic system. Lung cancer, also known as lung carcinoma, is characterized by uncontrolled cell growth in lungs. There are three major types of lung cancer: non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumor. Non-small cell lung cancer is the common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Common symptoms of lung cancer include coughing, chest pains, weight loss, and shortness of breath. Lung cancer can be treated through various types of therapies such as chemotherapy, radiation therapy, vaccines, and immunotherapies.  

According to Centers for Disease Control and Prevention (CDC), lung cancer is the primary cause of cancer death and the second most common cancer. The global lung cancer therapeutics market is expected to expand at a rapid pace during the forecast period due to the increase in incidence of lung cancer. Cigarette smoking, pipes, cigar smoking, and constant exposure to asbestos are the key factors that can cause lung cancer. Prominent factors driving the global lung cancer therapeutics market include increase in geriatric population and rise in prevalence of unhealthy lifestyles. Availability of generic drugs, poor cancer diagnostic facilities in many countries, high cost and the adverse effect of radiation and chemotherapies are the factors likely to restrain the global lung cancer therapeutics market during the forecast period. 

The global lung cancer therapeutics market can be segmented based on chemotherapy, targeted therapy, radiotherapy, and geography. Based on chemotherapy, the global lung cancer therapeutics market can be categorized into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine, and others. Chemotherapy is usually based on the combination of drugs. In terms of targeted therapy, the global lung cancer therapeutics market can be divided into Avastin, Tarceva, Iressa, Gilotrif, and others. Based on radiotherapy, the global lung cancer therapeutics market can be segregated into external beam radiotherapy, internal radiotherapy, and systemic radiotherapy. 

Geographically, the lung cancer therapeutics market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to dominate the global lung cancer therapeutics market in the near future, due to extensive technological advancements in the region. 

Europe is anticipated to be the second largest market for lung cancer therapeutics owing to the large government funding in the field of research and development of novel drugs and technological advancements in the fields of cancer. The global lung cancer therapeutics market in Asia Pacific is estimated to expand at a rapid pace the during the forecast period primarily owing to the development in healthcare facilities, rise in awareness about health, and increase in government funding. In terms of revenue, the lung cancer therapeutics market in China and India is likely to expand significantly owing to the increase in population, development of economies, rise in prevalence of unhealthy lifestyle, and surge in air pollution. 

Key players operating in the global lung cancer therapeutics market are adopting various strategies such as acquisition and mergers, development of new and efficient drugs, geographical expansion, and strong research and development activities in order to maintain their position in the market. Prominent players operating in the global lung cancer therapeutics market include F. Hoffmann-La Roche Ltd., AstraZeneca plc, GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., Pfizer, Inc., Agennix AG, and Eli Lilly and Company. 

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Lung Cancer Therapeutics Markets

Pre Book